<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877784</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201601374</org_study_id>
    <nct_id>NCT02877784</nct_id>
  </id_info>
  <brief_title>Screening in Oculopharyngeal Muscular Dystrophy</brief_title>
  <official_title>Determination of Accurate Screening Tools for Dysphagia in Oculopharyngeal Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathic disease that results in
      progressive degeneration of the oral and pharyngeal muscular, resulting in severe dysphagia
      and dysarthria. OPMD is considered a rare disease; therefore, limited research is available
      on the natural progression of the disease or the utility of biomarkers to identify swallowing
      impairment. The aim of this study is:

        1. To identify accurate, reliable and non-invasive clinical markers of swallowing
           impairment

        2. To determine the discriminate ability of these markers to identify impairments in
           swallow safety and swallowing efficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be recruited from the Neurology clinic at the University of Florida. The
      single evaluation will occur in the PIs research laboratory at the University of Florida,
      Gainesville, Florida.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic Imaging Grade of Swallowing Toxicity</measure>
    <time_frame>Baseline</time_frame>
    <description>Global Metric of swallowing Safety and Efficiency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary intake as confirmed by Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>Baseline</time_frame>
    <description>FOIS is a validated 7-point scale indexing an individual's ability to intake food on a day-to-day basis.
TUBE DEPENDENT (levels 1-3) No oral intake Tube dependent with minimal/inconsistent oral intake Tube supplements with consistent oral intake TOTAL ORAL INTAKE (levels 4-7) Total oral intake of a single consistency Total oral intake of multiple consistencies requiring special preparation Total oral intake with no special preparation, but must avoid specific foods or liquid items Total oral intake with no restrictions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant perception of swallowing related symptoms as confirmed by The Eating Assessment Tool 10 (EAT-10)</measure>
    <time_frame>Baseline</time_frame>
    <description>EAT-10 is a 10-item validated self-administered dysphagia severity symptom survey. Score is 0 - 40 with 0 being the best possible score and 40 the worst possible score.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Oculopharyngeal Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Screening</arm_group_label>
    <description>Participants enrolled will undergo testing of the swallowing mechanism</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Videofluoroscopic swallowing study</intervention_name>
    <description>Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.</description>
    <arm_group_label>Screening</arm_group_label>
    <other_name>VFSS</other_name>
    <other_name>modified barium swallow (MBS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional Oral Intake Scale</intervention_name>
    <description>The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.</description>
    <arm_group_label>Screening</arm_group_label>
    <other_name>FOIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eating Assessment Tool-10</intervention_name>
    <description>The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.</description>
    <arm_group_label>Screening</arm_group_label>
    <other_name>EAT-10</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The sample population will consist of individuals with a diagnosis of oculopharyngeal
        muscular dystrophy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of oculopharyngeal muscular dystrophy

          -  no allergies to barium or capsaicin,

          -  no tracheotomy or mechanical ventilation

          -  no significant concurrent respiratory disease (e.g., COPD).

        Exclusion Criteria:

          -  Pregnant Women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Plowman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening</keyword>
  <keyword>OPMD</keyword>
  <keyword>dysphagia</keyword>
  <keyword>dysarthria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Oculopharyngeal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

